For research use only. Not for therapeutic Use.
AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of Tazemetostat in endometrial cancer[1].
| Catalog Number | I040155 |
| CAS Number | 46697-00-1 |
| Synonyms | N-[(5,7-dichloro-2,3-dihydro-1-benzofuran-2-yl)methyl]propan-2-amine |
| Molecular Formula | C12H15Cl2NO |
| Purity | ≥95% |
| InChI | InChI=1S/C12H15Cl2NO/c1-7(2)15-6-10-4-8-3-9(13)5-11(14)12(8)16-10/h3,5,7,10,15H,4,6H2,1-2H3 |
| InChIKey | FCFGRTQYVIIVRZ-UHFFFAOYSA-N |
| SMILES | CC(C)NCC1CC2=C(O1)C(=CC(=C2)Cl)Cl |
| Reference | [1]. Lingli Chen, et al. Compound AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of tazemetostat in endometrial cancer. Cancer Lett. 2023 Dec 1:578:216445. |
